1. 23andMe received approval for its Personal Genome Service Pharmacogenetic Report, a direct-to-consumer DNA test that tells how the user’s genetics affect their responses to different medications.
2. Sympazan is an oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, a severe condition characterized by recurrent seizures that begin early in life.
3. Hyrimoz is Sandoz’s biosimilar of AbbVie’s rheumatoid arthritis drug Humira.
4. Invokana, an oral treatment, was approved to reduce the risk of major cardiovascular events in adults with Type 2 diabetes.
More articles on supply chain:
Amazon to sell exclusive brand of consumer medical devices
The 1st flu treatment in decades, a diagnostic test for menopause & more: 5 latest FDA approvals
Senate Democrats question if FDA’s digital health pre-certification will ‘compromise public safety’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.